Corning's Outlook Signals Sales Challenges In Q1, But CEO Foresees $3B Revenue Growth In Medium Term
Corning Incorporated GLW | 0.00 |
Corning Inc (NYSE:GLW) reported a fourth-quarter FY23 core sales decline of 10% year-on-year to $3.27 billion, beating the consensus of $3.25 billion. Core EPS of $0.39 was in line with the consensus.
Display Technologies sales grew by 11% Y/Y to $869 million. The sales declined 11% Q/Q due to a sequential volume decline.
Optical Communications sales declined by 24% Y/Y to $903 million. The sales decreased by 2% Q/Q due to temporarily lower demand from carrier customers.
Specialty Materials sales decreased by 6% Y/Y to $473 million. The 16% Q/Q decline followed strong third-quarter sales of smartphone cover materials for customer product launches.
Life Sciences sales decreased by 18% Y/Y to $242 million. The sales grew by 5% Q/Q, as customers in North America and Europe are completing their inventory drawdowns.
Environmental Technologies sales grew by 9% Y/Y to $429 million. The sales declined by 4% Q/Q, reflecting normal seasonality.
Core gross margin increased by 330 bps to 37%. The free cash flow improved to $487, up from $377 million a year ago.
Chair and CEO Wendell P. Weeks continued, “We are entering 2024 operationally strong, and we have an opportunity to increase our sales by more than $3 billion in the medium term as our markets normalize.”
Outlook: Corning sees first-quarter core sales of $3.10 billion (consensus $3.17 billion) and core EPS of $0.32 – $0.38 (consensus $0.38) and anticipates the first quarter to be the low quarter of the year.
Price Action: GLW shares traded higher by 6.50% at $33.18 on the last check Tuesday.
Photo via Wikimedia Commons
Recommend
- Sahm Platform 06/11 13:59
Google Unveils Its Most Powerful AI Chip Yet, Challenging Nvidia’s Market Dominance
Sahm Platform 07/11 03:01Amazon & Apple Soar, But the REAL Q3 Winner Hasn't Even Reported Yet. Check Out the Full Mag 7 Report Card
Insights 07/11 10:36$1000 Invested In L3Harris Technologies 10 Years Ago Would Be Worth This Much Today
Benzinga News 07/11 21:15FDA Places Clinical Hold On Tenaya Therapeutics' TN-201 Trial, Requests Protocol Amendment For Patient Monitoring And Immunosuppression Management
Benzinga News 07/11 21:26Cellectis Q3 Adj. EPS $0.02 Beats $(0.28) Estimate, Sales $37.164M Beat $6.900M Estimate
Benzinga News 07/11 21:32Canaccord Genuity Maintains Buy on Arq, Lowers Price Target to $8
Benzinga News 07/11 21:37Canaccord Genuity Maintains Buy on JFrog, Raises Price Target to $65
Benzinga News 07/11 21:43


